Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 205.63

-0.7%

1:57 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John O'Neill who wrote (21002)	5/25/1998 11:15:00 AM
From: WTDEC	Read Replies (1) of 32384

" I believe the patent would be contested once a company starts selling the product. I guess, if Roche wanted to, they could sue for patent infringement after FDA approval and selling of Panretin by LGND. Sounds like Roche would also be taking on LLY in this, if they chose to pursue the matter" JO, I believe the US Patent and Trademark Office (PTO) already initiated an interference when Roche filed the patent(s) making claims which overlapped the LGND patent(s). My understanding is that product sales are not required as PTO already knows of the overlap. Also, I don't think Panretin is involved in the LLY deal (the patents in question might be, although I see that as rather unlikely) so I believe Roche would only be taking on LGND here. See my post to HN from yesterday for more info. With NDA for Panretin gel to be filed this week, this patent issue is going to be more visible. LGND should update investors on where things stand IMO. Regards, Walter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next